login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
VIR BIOTECHNOLOGY INC (VIR) Stock News
USA
- NASDAQ:VIR -
US92764N1028
-
Common Stock
6.27
USD
+0.49 (+8.48%)
Last: 10/20/2025, 8:20:58 PM
6.2999
USD
+0.03 (+0.48%)
After Hours:
10/20/2025, 8:20:58 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
VIR Latest News, Press Relases and Analysis
All
Press Releases
12 days ago - By: Vir Biotechnology, Inc.
Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer
14 days ago - By: Vir Biotechnology, Inc.
Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD’s The Liver Meeting® 2025
2 months ago - By: Benzinga
- Mentions:
DSP
MRVL
CRWV
KARO
...
This Astera Labs Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday
3 months ago - By: The Motley Fool
Vir (VIR) Q2 Revenue Drops 61%
3 months ago - By: Benzinga
- Mentions:
OEC
VTLE
DIN
INSE
...
Earnings Scheduled For August 6, 2025
2 months ago - By: Yahoo Finance
- Mentions:
LLY
HSBC
SBAC
T-PA
...
Micron initiated, Eli Lilly upgraded: Wall Street's top analyst calls
2 months ago - By: Vir Biotechnology, Inc.
Vir Biotechnology to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
3 months ago - By: Zacks Investment Research
- Mentions:
FEMY
Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates
3 months ago - By: Vir Biotechnology, Inc.
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results
3 months ago - By: Vir Biotechnology, Inc.
Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta
3 months ago - By: Vir Biotechnology, Inc.
Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta
3 months ago - By: Vir Biotechnology, Inc.
Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors
3 months ago - By: Vir Biotechnology, Inc.
Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025
5 months ago - By: Vir Biotechnology, Inc.
Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025
5 months ago - By: Vir Biotechnology, Inc.
Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit
5 months ago - By: Vir Biotechnology, Inc.
Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference
6 months ago - By: Vir Biotechnology, Inc.
Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study
6 months ago - By: Zacks Investment Research
- Mentions:
AGEN
Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Lags Revenue Estimates
6 months ago - By: Vir Biotechnology, Inc.
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results
6 months ago - By: Vir Biotechnology, Inc.
Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025
6 months ago - By: Vir Biotechnology, Inc.
Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025
6 months ago - By: Yahoo Finance
- Mentions:
IOVA
DAWN
ARVN
NUVB
...
Iovance Biotherapeutics, Inc. (IOVA): Among Stocks Under $10 that Will Triple
6 months ago - By: Yahoo Finance
- Mentions:
RLAY
KIND
GOSS
DAWN
...
Relay Therapeutics, Inc. (RLAY): Among Stocks Under $10 that Will Triple
6 months ago - By: Yahoo Finance
- Mentions:
GOSS
PRLD
DAWN
NUVB
...
Gossamer Bio, Inc. (GOSS): Among Stocks Under $10 that Will Triple
6 months ago - By: Yahoo Finance
- Mentions:
NUVB
RLAY
TSLA
DAWN
...
Nuvation Bio Inc. (NUVB): Among Stocks Under $10 that Will Triple
6 months ago - By: Yahoo Finance
- Mentions:
ARVN
DAWN
WMT
NUVB
...
Arvinas, Inc. (ARVN): Among Stocks Under $10 that Will Triple
6 months ago - By: Yahoo Finance
Vir Biotechnology, Inc. (VIR): Among Stocks Under $10 that Will Triple
Please enable JavaScript to continue using this application.